PRIMACOR
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRIMACOR is an injectable small-molecule inotropic agent approved in 1987 by Sanofi. The drug's mechanism of action and specific indications are not publicly detailed in this dataset, but injectables of this era typically address acute hemodynamic support. Patient population is likely limited to acute care settings.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a mature brand with shrinking team resources and minimal growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal hiring activity on PRIMACOR; this is a maintenance-phase brand with limited career mobility or growth. Professionals on this team should plan transitions to growth-stage products or adjacent therapeutic areas.
Brand ManagerCommercial Operations
Worked on PRIMACOR at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.